Dehydration

BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
星期一, 五月 6, 2024
Net, Skin, Investment, Solubility, Research, Diabetes, BioCryst Pharmaceuticals, Plasma, Injection, Webcast, Kallikrein, Prescription, Disease, Dehydration, Patient, Eye, Operating cost, Physician, Paratriathlon, EPS, Workforce, Infection, DME, Clinical trial, HAE, Diabetic retinopathy, Edema, Genetic disorder, GAAP, Netherton syndrome, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., May 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • These two successes helped us exceed our revenue projections for the quarter and, as a result, we are increasing our revenue guidance for 2024,” said Charlie Gayer, chief commercial officer of BioCryst.
  • Interest expense was $24.5 million in the first quarter of 2024, compared to $27.4 million in the first quarter of 2023 (-10.6 percent y-o-y).
  • Our references to our first quarter 2024 “non-GAAP pro forma” financial measures of adjusted net loss and adjusted earnings per share constitute non-GAAP financial measures.
  • ET today to discuss the financial results and provide a corporate update.

Feinstein Institutes study challenges the use of thick liquid diets in hospitalized patients with dementia and dysphagia

Retrieved on: 
星期一, 五月 6, 2024
Science, Neurology, Research, General Health, Health, Mental Health, Fitness & Nutrition, Other Health, Dysphagia, JAMA, Pneumonia, Oropharyngeal dysphagia, Hospital, Northwell Health, American Medical Association, Death, DRS, Dehydration, Patient, Intubation, Malnutrition, Medical research, Multimedia, Paper, Internal medicine, Credit, Dementia, Quality of life, Journal, Cohort (statistics), Prevalence, Nursing

Although dysphagia diets, consisting of thick liquids, are widely used, it is unknown whether thick liquids improve patient outcomes.

Key Points: 
  • Although dysphagia diets, consisting of thick liquids, are widely used, it is unknown whether thick liquids improve patient outcomes.
  • Contrary to expectations, the study found no significant difference in hospital mortality between patients receiving thick and thin liquids.
  • This primary outcome raises important questions about the benefits of thick liquids for dysphagia management in hospitalized patients with ADRD.
  • These studies should integrate instrumental assessments such as Modified Barium Swallow Studies (MBSS) to assess the influence of thick liquids on clinical outcomes in hospitalized patients with ADRD and dysphagia.

Petco Shares New Summer Collections and Tips for Safe, Stylish Outdoor Fun

Retrieved on: 
星期三, 五月 8, 2024
Lead, Pet, Travel, Checklist, Love, Collection, Parent, Water, Cat, Reward, Reddy, Dehydration, Adventure, Dog, Flea, SAN, Overheating

SAN DIEGO, May 8, 2024 /PRNewswire/ -- With summer around the corner, pets and pet parents will soon be spending even more time together outdoors. This year, Petco is helping pet parents prepare for all types of summer activities – from pool "pawties" and barbeques to travel and adventures – with new essentials designed to keep pets safe, cool and stylish all season long at an affordable price point.

Key Points: 
  • Summer is also a great time to visit the vet for a routine check-up and confirm pets are up to date on their vaccinations.
  • Beat the heat: It's always important to look out for and prevent overheating and dehydration in pets, but especially during the hotter summer months.
  • Pet parents can find their pets' summer essentials at Petco pet care centers nationwide, at petco.com and via the Petco app.
  • Petco offers various convenient ways to shop including buy online, pick up in store, curbside pick-up and same-day delivery.

Epicore Biosystems Wins 2024 Red Dot Award for Exceptional Product Design

Retrieved on: 
星期二, 五月 7, 2024
Red Dot, Military personnel, Climate change, Agriculture, Mining, Red, Dehydration, Thermoregulation, Connected, Safety, Athlete

CAMBRIDGE, Mass., May 7, 2024 /PRNewswire/ -- Epicore Biosystems ('Epicore') , a digital health company developing advanced sweat-sensing wearables to provide real-time personalized hydration insights for performance and safety, today announced Connected Hydration has been awarded the Red Dot Award for exceptional product design.

Key Points: 
  • CAMBRIDGE, Mass., May 7, 2024 /PRNewswire/ -- Epicore Biosystems ('Epicore') , a digital health company developing advanced sweat-sensing wearables to provide real-time personalized hydration insights for performance and safety, today announced Connected Hydration has been awarded the Red Dot Award for exceptional product design.
  • The Red Dot Award is an internationally recognized seal for excellence in design innovation.
  • Winners around the world are determined by expert juries in the areas of product design, communication design and design concepts.
  • "We are honored to be recognized for product design excellence by the design jurists at Red Dot," said Stephen Lee, Chief Technology Officer at Epicore Biosystems.

How to Support Your Pet's Health During Summer

Retrieved on: 
星期一, 四月 29, 2024
Relaxation, Veterinarian, Element, Weather, Explosion, Pet, Travel, Fourth, Health, Heart, Pollen, Allergy, Appetite, Weakness, Allergen, Human, Exercise, Dehydration, Noise, Nutrient, Season, Anxiety, Growth, Drinking

Veterinarians can offer advice on allergy support and supplements appropriate for your pet's age, breed and size.

Key Points: 
  • Veterinarians can offer advice on allergy support and supplements appropriate for your pet's age, breed and size.
  • Fireworks: Summer tends to bring more loud noise and commotion in general, but this is especially true around the Fourth of July when explosions become the norm.
  • Dehydration: Just like humans, hotter temperatures make it easier to get dehydrated, which can lead to myriad health concerns.
  • The vet-formulated soft chew line was designed to offer a streamlined and personalized supplement approach for breeds with particular health needs.

Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
星期四, 五月 2, 2024
Sale, Nephrology, Diarrhea, Investment, Safety, Risk, Food, Research, Human, Corporate development, Hyperphosphatemia, Dehydration, Incidence, Patient, Abdominal distension, Death, Growth, Rat, Pharmaceutical industry

WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

Key Points: 
  • “The first quarter of 2024 marked an important milestone for Ardelyx as a commercial company.
  • Ardelyx currently expects full-year 2024 U.S. net product sales revenue for IBSRELA to be between $140.0 and $150.0 million.
  • U.S. net product sales revenue during Q1 2024 was $15.2 million, the first full quarter of sales following the product’s launch in November 2023.
  • R&D Expenses: Research and development expenses were $10.6 million for the quarter ended March 31, 2024, compared to $9.1 million for the quarter ended March 31, 2023.

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection

Retrieved on: 
星期三, 四月 24, 2024
Urine, Kidney, FDA, Shanda, Embolism, Huber loss, Hepatic encephalopathy, Uric acid, Oliguria, Congestion, Blood volume, Furosemide, Organic acid, Deafness, Erythema, Cerebral edema, Ascites, Tinnitus, History, Thrombosis, Creatinine, NYHA, Dehydration, BUN, Patient, Hypersensitivity, Ototoxicity, Anuria, Glucose, Azotemia, Hypoproteinemia, CO2, Diuresis, Cirrhosis, Chronic kidney disease, Edema, Urinary retention, Bruise, Growth, Benign prostatic hyperplasia, Coma, Heart failure, Pharmaceutical industry

BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has enrolled the first participant in the pivotal pharmacokinetic (PK) study of SCP-111 (furosemide 80 mg/mL), an investigational, low volume, pH neutral formulation of furosemide administered via an auto-injector.

Key Points: 
  • The auto-injector is being developed as a complement to the FDA approved On-body Infusor in an effort to provide patients with a subcutaneous injection and prescribers with treatment flexibility.
  • If approved, the Company believes the auto-injector also has the potential to meaningfully reduce manufacturing costs.
  • FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema.
  • The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.

FSIS ISSUES PUBLIC HEALTH ALERT FOR GROUND BEEF PRODUCTS DUE TO POSSIBLE E. COLI O157:H7 CONTAMINATION

Retrieved on: 
星期六, 四月 20, 2024
Food safety, Syndrome, Person, Poultry, Dysentery, Independence Avenue, Commerce, Kidney failure, USDA, Human, H7, Dehydration, HUS, TDD, Pallor, Meat, Temperature, Chronic pain, FSIS, Bruise, Office for Civil Rights, Civil and political rights, Poultry farming

WASHINGTON, April 20, 2024 – The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) is issuing a public health alert for ground beef products that may be contaminated with E. coli O157:H7.

Key Points: 
  • WASHINGTON, April 20, 2024 – The U.S. Department of Agriculture’s Food Safety and Inspection Service (FSIS) is issuing a public health alert for ground beef products that may be contaminated with E. coli O157:H7.
  • FSIS is issuing this public health alert to ensure that consumers are aware that these products should not be consumed.
  • The products have a “Use/Freeze by” date of April 22, 2024, and packaging date of “032824.” The list of products that are subject to the public health alert can be found here .
  • The company notified FSIS that they inadvertently used a portion of the contaminated beef to produce ground beef products that they subsequently shipped into commerce.

BranchOut Food Strengthens Financial Position with Successful Sale of Senior Secured Promissory Notes and Warrants

Retrieved on: 
星期三, 四月 17, 2024
Sale, Warrant, Food technology, Public expenditure, Senior, Dehydration, Subscription business model, Fruit, Security, Control, Security (finance)

BEND, Ore., April 17, 2024 (GLOBE NEWSWIRE) -- BranchOut Food Inc. (NASDAQ: BOF), a food technology company and maker of dehydrated fruit and vegetable-based products, today announced that it has completed the sale of $225,000 of Senior Secured Promissory Notes ("Notes") and Warrants to purchase an aggregate of 56,250 shares of the Company’s common stock.

Key Points: 
  • BEND, Ore., April 17, 2024 (GLOBE NEWSWIRE) -- BranchOut Food Inc. (NASDAQ: BOF), a food technology company and maker of dehydrated fruit and vegetable-based products, today announced that it has completed the sale of $225,000 of Senior Secured Promissory Notes ("Notes") and Warrants to purchase an aggregate of 56,250 shares of the Company’s common stock.
  • Each Warrant is exercisable for a ten-year period at an exercise price of $2.00 per share.
  • The Company has board approval to borrow up to $2,000,000 of Notes.
  • The sale was made to a group of seven investors pursuant to a First Amendment to Subscription Agreement dated April 15-16, 2024.

Global Dermocosmetic (Skin, Hair) Market Analysis Report 2024: Innovations in Bioengineering Transforming the Industry - Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
星期三, 四月 17, 2024
Cosmetics, Retail, General Health, Health, Online, USD, Market, Supermarket, Sale, Dermatitis, Porter's five forces analysis, Epidemiology, Acne, SWOT, Particulates, Skin, AI, Genetic engineering, John Foster Dulles, Pharmacy, Life, Dermatology, Algorithm, Dehydration, Incidence, Patient, Hyperpigmentation, Psoriasis, Dermatologic Clinics, Rosacea, Child, Beauty, Biological engineering, Urbanization, Ageing, Fermentation, UV, Prevalence, Air pollution, Beauty salon

The market was valued at USD 67.42 Billion in 2023 which is expected to reach USD 108.94 Billion in 2030.

Key Points: 
  • The market was valued at USD 67.42 Billion in 2023 which is expected to reach USD 108.94 Billion in 2030.
  • This report provides a complete analysis for the historical period of 2020-2023, estimates of 2024 and the forecast period of 2025-2030.
  • The report presents the analysis of Dermocosmetic Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
  • Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.